Valeant Pharmaceuticals International Stock Hits New 52-Week High (VRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Valeant Pharmaceuticals International (NYSE: VRX) hit a new 52-week high Thursday as it is currently trading at $60.01, above its previous 52-week high of $59.99 with 885,924 shares traded as of 12:50 p.m. ET. Average volume has been 1.9 million shares over the past 30 days.

Valeant Pharmaceuticals International has a market cap of $17.86 billion and is part of the health care sector and drugs industry. Shares are up 27% year to date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. The company has a P/E ratio of 309.4, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk. You can view the full Valeant Pharmaceuticals International Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null